DTx West 2019

February 26 – 28 | San Mateo, CA

Defining How to Achieve Commercial and Patient Success with Digital Therapeutics

DTx West Partners
Partners

Key Numbers of DTx

200+

Attendees

Be part of the 200+ person audience of senior executives who are driving forward the development of Digital Therapeutics

30+

Expert Speakers

Learn from the industry-defining speaker faculty, comprised of the pioneers of the industry and the most exciting new-comers

10

Hours of Networking

The audience is the  who’s who of the industry. From every leading Digital Therapeutic company to Pharma, HCP’s and Investors

What people are saying about DTx

“I found this conference eye-opening and had many interesting conversations. I am blown away by the Digital Therapeutics community and its commitment to value-based care”

Founder and Executive Director, Cures Within Reach for Cancer
Laura Kleiman

“DTx is the must attend event in our industry”

CEO, Akili Interactive
Eddie Martucci

“The DTx Series is a fantastic set of meetings. The quality of the investors, entrepreneurs and companies never fails to impress me, and I always leave having learned a lot”

General Partner, JAZZ Venture Partners
John Spinale

“The conference was tangible, specific and open. I have never been to a conference of this size with such richness of discussion”

Health Data Policy Director, Novartis
Frederico Calado

“Thanks for catalyzing the industry forward in this emerging field.  Looking forward to the next one”

Global Director, Innovation, Johnson and Johnson Technology
Cris de Luca

“DTx is an inclusive event, where the participants truly believe that the rising tide will raise all boats”

Founder and CEO, MyMee Inc 
Mette Dyhrberg

Expert Speaker Faculty

Sean Duffy

Co-Founder & CEO, Omada Health

Sean Duffy is the co-founder and CEO of Omada Health, a digital behavioral medicine company dedicated to inspiring and empowering people everywhere to live free of chronic conditions like heart disease and type 2 diabetes. In 2016, Omada was named a Technology Pioneer by the World Economic Forum, and in 2015 and 2017, the company was recognized as one of Fast Company’s Most Innovative Companies. Prior to Omada, Sean worked at both Google and IDEO. A former MD/MBA candidate at Harvard, he holds a BS in neuroscience from Columbia University.

Anand Iyer

Chief Strategy Officer, WellDoc

Anand is a respected global digital health leader—most known for his insights on and experience with technology, strategy and regulatory policy. Anand has been instrumental in WellDoc’s success and the development of BlueStar®. Since joining WellDoc in 2008, he has held core leadership positions that included Chief Data Science Officer, President and Chief Operations Officer. He holds an MS and a PhD in electrical and computer engineering, and an MBA from Carnegie Mellon University

Stephanie Tilenius

CEO, Vida Health

Stephanie Tilenius is the Founder and CEO of Vida Health, a digital therapeutics platform that helps individuals overcome chronic mental and physical health conditions once and for all. Vida is deployed at Fortune 500 companies, large national payers, and providers.

Prior to starting Vida, Tilenius was with Kleiner Perkins Canfield & Byers, where she worked primarily with late-stage KPCB portfolio companies, with an emphasis on companies in the Digital Growth Fund.

Prior to Kleiner, Stephanie was at Google, where she was Vice President of Global Commerce and Payments, helping build and launch new products and platforms including Google Wallet, Google Shopping and Google Express.

Before Google, she was at eBay and PayPal for nine years. In her last role, she was SVP of eBay.com and Global Product, where she helped lead the eBay Marketplace turnaround from negative to positive double-digit growth.

Prior to eBay, Stephanie was VP of Merchant Services at PayPal where she built the off-eBay PayPal business from the ground up into a multi-billion business.

Today, she is using her experience in building engaging consumer products to transform healthcare. Vida combines digital therapies with one-on-one health coaching and evidence-based programs to help individuals overcome costly chronic conditions like obesity, diabetes, COPD, and depression.

Eugene Borukhovich

Global Head, Digital Health Incubation & Innovation, Bayer

Mette Dyhrberg

CEO, Mymee

Eddie Martucci

CEO, Akili Interactive Labs

Eddie co-founded Akili Interactive Labs, and as part of PureTech has co-founded two other health-focused start-ups, and helped launch their digital health initiative. He was previously a Kauffman Entrepreneur Fellow, a program sponsored by the Kauffman Foundation of Kansas City, MO, focused on healthcare entrepreneurship. Prior to that, he completed his graduate work at Yale University in the Departments of Pharmacology and Molecular Biophysics & Biochemistry, focusing on structure-based drug design, where he led a research project that identified two novel chemical scaffolds as proof-of-concept compounds for novel therapy. Eddie received his B.S. in Biochemistry from Providence College, and his M.Phil. and Ph.D. from Yale University.

Brian Harris

Co-Founder & CEO, MedRhythms Inc.

Alex Waldron

Chief Commercial Officer, Pear Therapeutics

Alex is a senior level global bio/pharmaceutical business leader with 27+ years of experience with large pharmaceutical, fully integrated biopharmaceutical and startup organizations. He has a proven record of building and leading business strategy and operations. In his career, Alex has driven enterprise value from portfolio strategy through to commercial launch. In previous roles, Alex has architected the structure and growth of several divisions at Biogen and helped to shape the emerging biosimilar market at Epirus Biopharmaceuticals. Alex has also worked in numerous commercial and operations roles at Genzyme, Astra Zeneca, Pfizer and Bristol-Myers Squibb.

André Heeg

Head of Digital, Sandoz

André is an experienced startup executive, business and sales manager, leader, and strategist. He is an expert in inside and field sales management, pharmaceutical and medical products marketing and sales, commercial strategy planning, and healthcare topics. He has extensive knowledge in B2B and B2C business, software and hardware product portfolios and offerings in the US and Germany. His passion for the impact technology can have on a large scale has been the red thread throughout his career. André holds doctorates from the University of Würzburg in medicine and the University of Freiburg in dental medicine.

André joined Sandoz in June 2018 from his role as CSO at Thermondo GmbH, an integrated energy company offering state-of-the-art energy efficiency services and applying digital process excellence and quality management. This year, The Financial Times named Thermondo #2 fastest growing company in Europe as well as one of the 100 most influential clean-tech companies in the world.
Before that, André was Vice President of Local Sales at Zocdoc, Inc. Zocdoc is an online service that identifies in-network neighborhood physicians, books appointments, shares patient reviews, provides appointment and check-up reminders, and automatically fills in paperwork. Zocdoc is free for patients and available across the United States.

Chris Wasden

Head of Pharma, Happify

Megan Jones-Bell

Chief Scientific Officer, Headspace

Dr. Megan Jones Bell is Chief Science Officer at Headspace, a leader in the field of digital health and a visionary in making mental health care more effective, affordable, and accessible to all populations. Megan leads the company’s seven-person Health and Science team, which focuses on clinically validating the benefits of meditation with Headspace and commercializing the product within healthcare. Megan also oversees the 65+ clinical research studies conducted by Headspace’s academic partners.

Joel Sangerman

Chief Commercial Officer Click Therapeutics

Joel serves as Chief Commercial Officer for Click Therapeutics. Click develops software as prescription medical treatments to improve the lives of patients throughout the world.

For over 25 years Joel has helped payers, employers, providers and suppliers achieve better patient outcomes at a lower cost of care using new health technology. Helping to lead the charge for healthcare innovation, Joel will share how employers, insurers, and other healthcare payers are adopting Click’s clinically-validated digital therapeutics as key components to population health strategies.

While at Johnson & Johnson as Director of Payer Relations and with Walgreens as Vice President of Market Development Joel initiated pay for performance and shared savings models of value-based purchasing with payers and health systems. Joel also led commercial efforts with Sanofi Aventis to help providers contain the exploding costs associated with chronic conditions such as diabetes and cardiovascular disease.

Joel graduated from DePaul University in Chicago and later completed a Fellowship in healthcare leadership with the Washington DC based Advisory Board Company.

Rosemary Ku

Urgent Care Physician Kaiser Permanente | Founder, Executive Director, Cure Chronic Disease

Rosemary Ku, MD/MBA/MPH, is a practicing physician dual-board certified in Internal Medicine and Preventive Medicine and the founder of Cure Chronic Disease, the only digital health nonprofit dedicated to reversing multiple chronic diseases at scale. The patent pending technology creates ``n of one`` experiences by generating personalized treatment plans that iterate based on how an individual's conditions respond.

Rosemary previously served as the Chief Medical and Strategy Officer of Restore Health (acquired by Zillion in 2017). Restore Health was one of the most clinically effective digital solutions for factors of metabolic syndrome with a 77% reversal rate. During that time, Rosemary's role spanned clinical leadership, product development, and commercialization. Rosemary completed residency at Kaiser Permanente San Francisco and medical school at Columbia University College of Physicians and Surgeons. She obtained her MPH in Health Policy and Administration from UC Berkeley and MBA from Columbia Business School. Rosemary majored in Molecular Biology with a certificate in Neuroscience at Princeton University.

David Stevenson

Managing Director, Merck Global Health Innovation Fund

Edward Cox

CEO, Dthera Sciences

Edward Cox was appointed as the new Chairman of the Board and the Chief Executive Officer of Dthera in connection with the closing of the EveryStory Transaction. Mr. Cox also continues to serve as EveryStory’s President and Chief Executive Officer and Chairman and a member of EveryStory’s Board of Directors, positions he has held since February 6, 2015. Prior to that, he served as a Vice President and Executive Officer of Apricus Biosciences, Inc., a publicly traded company, since December 2009, in roles leading Commercial Development, Business Development, Investor Relations, and Corporate Development. Mr. Cox holds a Master of Science in Management degree from the Warrington College of Business Administration at the University of Florida.

Jeremy Sohn

VP & Global Head, Digital Business Development & Licensing, Novartis

Brent Vaughan

CEO & Co-Founder, Cognoa

Brent is the CEO and co-founder of Cognoa, an AI-based digital precision medicine behavioral health platform. Cognoais developing innovative digital diagnostics and digital therapeutics to change the standard of care for pediatric behavioral health and improve outcomes by enabling earlier diagnosis, treatment, and increased engagement. Brent has over 20 years industry experience working with diagnostics, therapeutics and digital consumer health. Prior to Cognoa, Brent was the co-founder and COO of WellnessFX, an award-winning digital health company that increased patient engagement by providing direct-to-consumer diagnostics and integrated telemedicine. Before working in digital health, Brent worked in product and commercial roles in Novartis, Nektar, Roche and Lily.

David Amor

VP, Quality & Regulatory Affairs, Pear Therapeutics

David Amor is an FDA/ EU Quality/ regulatory expert focused on combination products and digital health. From NDAs and 505(b)(2)s to mobile app 510(k)s and Pre-INDs/ Q-subs, David has worked with over 45 medical device and pharmaceutical companies – large and small alike- supporting and/ or leading regulatory submissions and implementing quality management systems, including alignment of Agile-based SDLC programs to FDA and EU requirements. He co-founded RemindTrac in 2014 (www.remindtrac.com), a digital health company for chronic patients, that continues to pioneer mobile care management systems today, and sold his consulting firm Medgineering in 2016.

David has recently led QA/RA strategy groups at Teva within the Digital Health Group, particularly in development of Agile-based Quality Management Systems, was a Principal Consultant in the CP/DH (Combination Products, Digital Health) group at Qara Partners, and served as the in-house risk management subject matter expert at Abbott (St. Jude Medical). He has served as the Director or VP of Quality at other medical device start-ups including AdrenaCard, Calcula, Enspero Medical and various others, and led multiple organizations through 483 and Warning Letter remediation projects, namely associated with risk management and design history file deficiencies, including Pfizer (Hospira), MID, Boston Scientific and St. Jude Medical.

Ruchita Sinha

Senior Director, Investment, Sanofi Ventures

Ruchita Sinha is Sr. Director of Investments at Sanofi Ventures where she invests in biopharma and digital health opportunities. She led Sanofi’s investments in Inozyme, Omada Health, Evidation Health, Curisium, and also manages investments in Science 37 and Common Sensing. Prior to Sanofi, Ruchita was at GE Ventures, where she served as a board observer for HeadSense Medical and Caremerge and managed GE’s investments in CheckCap (Nasdaq: CHEKU) and HeartFlow. She also managed GE’s seed-stage portfolio of digital health investments in partnership with StartUp Health.

Ruchita has more than 15 years of healthcare experience in pharma, biotech, medical devices, and digital health. Previously, Ruchita was at Pfizer’s Strategy, BD, & Portfolio Management group, and a management consultant with LEK Consulting. Ruchita started her career with Maxygen, an early stage biotech company. She holds an MBA from the University of Chicago, an MS in Cellular and Molecular Biology from the University of Wisconsin-Madison, and a BS in Biochemistry from Mount Holyoke College.

Giangiacomo Rocco di Torrepadula

CEO & Co-Founder AMICOMED

Sharief Taraman

Chief Medical Officer, Cognoa | Chief of Neurology, Children’s Hospital of Orange County

Taylor Mahan-Rudolph

Director, Quality & Regulatory, Propeller Health

David Kim

CEO, DigiTx Partners

David is the CEO of DigiTx Partners, bringing both business and clinical expertise to venture capital with an extensive background practicing medicine and building healthcare software companies. Most recently, Dr. Kim served as the COO of Lumiata, a venture-backed predictive analytics company positioned at the intersection of data science and medical science. Prior to Lumiata, he spent over a decade as an investor evaluating and growing healthcare companies at MPM Capital and Pinnacle Ventures. Before entering the business sector, David practiced as a general internist and hospitalist at Kaiser South San Francisco where he also served as the Director of Urgent Care and Assistant Chief of Internal Medicine.

Shahram Seyedin-Noor

Founder & General Partner, Civilization Ventures

Shahram is the Founder and General Partner of Civilization Ventures, a fund focused on supporting cutting-edge innovations in synthetic biology and health tech, including genomics, diagnostics, AI and regenerative medicine. Founded in 2017, Civilization VC has already been recognized by SVB as one of the most active funds in diagnostics. The fund’s disruptive seed portfolio includes CatalogDNA and Evonetix, as well as gene therapy leader Rocket Pharma (NASDAQ: RCKT). Prior to starting Civilization VC, Shahram was a founding executive in several life sciences companies, including Rgenix, a biotech company with first-in-class cancer drugs now in clinical trials, and NextBio, a big data genomics pioneer which he helped grow to over 50 people with millions in sales before it was acquired by Illumina. As an angel investor earlier in his career, Shahram provided the first check into Omada Health and was a seed investor in Counsyl (acq. by Myriad), Bina (acq. by Roche) and Avantome (acq. by Illumina). Shahram obtained his JD from Harvard Law School, where he was elected Editor-in-Chief of the Harvard International Law Journal, and has a BA in Economics from Pomona College.

Matthias Zenker

Partner, GAIA AG

Matthias is a physician by training and holds a medical doctorate degree from the University of Ulm, Germany. He has gained both inpatient and outpatient medical expertise in various healthcare systems around the world. Matthias joined GAIA 17 years ago and takes the responsibility for the national and international business development and licensing activities with payer and physician organisations as well as industry partners. And when not travelling the world for business, he travels the world for leisure.

Chris Raine

Founder & Chief Executive Officer, Hello Sunday Morning

Chris is the Founder and CEO of Hello Sunday Morning - an organisation that builds digital therapeutics focused on supporting people to change their relationship with alcohol.

David Klein

CEO, Click Therapeutics

Sasha Said

Vice President, Leerink Transformation Partners

LTP is a $313M growth equity fund investing exclusively in digital health and healthcare services. Sasha K. Said is a founding member of the LTP investment team where she sources and structures deals; provides representation for LTP on the Board of Directors; and provides strategic and tactical support to portfolio companies. She has 10 years of investing experience across asset classes, 4 of which were spent with Waypoint Capital, the multi-billion dollar investment group that represents the Bertarelli family. While there she helped launch a $2B life science fund, Gurnet Point Capital, now managed by Chris Viehbacher (former CEO of Sanofi), as well as built their corporate venture group with a strategy in digital health. Prior to Waypoint, Sasha was a Global Long/Short Public Equity and Private Equity Analyst at Water Asset Management, a global hedge fund in New York City.

Sasha serves as a Board Observer on the Boards of Vera Whole Health and Health Catalyst and is a Board Member of Rimedio, an early stage pharma services company. She is founder of Breaking7% (B7), a group of 122 women (51% senior/ 49% junior) in deal making roles in Boston who meet monthly to exchange deals and contacts. She is also an Advisor to Pulse companies, Massachusetts’ digital health accelerator.

Peter Hames

Co-Founder & Chief Executive Officer, Big Health

Peter Hames is co-founder and CEO of Big Health, a company creating “digital medicine” - automated, digital, behavior change programs for mental health that are as scalable as drugs yet as effective as in person therapy. Peter is an NHS Innovation Fellow, and holds a Masters in Experimental Psychology from Oxford University. It was his own experience of insomnia, and how he overcame it, that inspired him to found Big Health and create Sleepio, a digital sleep improvement program that is now available to over 1 million employees as part of their benefits package.

Debra Reisenthel

President & Chief Executive Officer, Palo Alto Health Sciences

Debra is founding CEO of Palo Alto Health Sciences, a digital therapeutic company providing evidence-based, at-home, drug-free solutions in behavioral health. Freespira® is an FDA-cleared treatment for panic disorder, panic attacks and symptoms of panic. Debra has broad operational and leadership experience in start- ups as well as large corporations. Prior to PAHS, Debra worked with a Bay Area incubator to develop a women’s health product, was founding CEO of Novasys Medical, and was VP/GM of a Division of Tyco, inc. (Mallinckrodt, Nellcor). Debra holds an MBA and R.R.T credentials. She has been a guest entrepreneur for 5 years as part of a Harvard Business School case study and supports entrepreneurs through her work with Astia and with CSweetner as a mentor to female executives.

Owen McCarthy

Co-Founder & President, MedRhythms Inc.

Anil Jina

Senior Vice President, Head of Medical Affairs, Akili Interactive

Austin Speier

Chief Strategy Officer, Click Therapeutics

Adam Kaufman

President & Chief Executive Officer, Canary Health

Adam Kaufman is a health pioneer, having led the building of digital behavior change programs used by dozens of healthcare organizations and tens of thousands of consumers. A health economist, engineer and company executive, Adam speaks to audiences nationwide on the accelerating trend of chronic illness, its impact on lives and costs of care and proven approaches to arresting disease trajectories.
Recognized as a leader in patient engagement and population health, Canary Health works with health plans such as Kaiser Permanente, Humana, GEHA and Blue Shield of California to empower members to better health self-management.

Jeffrey Abraham

Vice President, Market Access & Trade, Akili Interactive

Scott Kellogg

Senior Vice President, Medical Devices, Akili Interactive

Mr. Kellogg has worked in the medical device life-science industry for over 27 years and is currently the SVP in charge of medical devices (including RA, QA, GMP, and Clin Ops) at Akili Interactive Labs, Inc. Prior to joining Akili, Mr. Kellogg was an integral member of the founding teams at Follica Bio, Afferent, Corp., Sontra Medical, Inc., and UltraCision, Inc., where he served as the Vice President of Business Operations, Vice President of Product Development, Vice President of R&D, and Director of Engineering, respectively.

In these leadership roles, Mr. Kellogg was focused on commercializing novel medical technology. The technologies included digital therapy, surgical modalities, transdermal analyte detection, point-of-care diagnostics, transdermal drug delivery, neuro-stimulation, and therapeutic drug/device combinations. Additionally, he served in lead project management roles at Mentor Medical, Inc. and Ethicon Endo-Surgery, Inc (J&J). His broad experience includes product development/engineering, regulatory strategy/oversight, clinical design/operations, GMP & QSR establishment/compliance, intellectual property, and business development/strategic partnerships.

Mr. Kellogg graduated with high honors from the University of Massachusetts at Amherst with a BS in Engineering and received his MS and MBA from Northeastern University. He is an inventor on many domestic and international patents and the lead inventor on key patents for the Harmonic Scalpel ($1B/year product). In 2004 he and his team were awarded Popular Science’s “Best of what’s new in health care.”

James Musick

Vice President & Head, Neurology Patient Technology, UCB

Seth Coombs

Vice President, Oncology & Injectable Products, Sandoz

“I really enjoy DTx. The focused agenda keeps the audience well engaged and I learn a lot from the diverse insights and perspectives from the audience. It’s fantastic to have such a cross sector showing at the summit”

Joris Van Dam, Executive Director, Head of Digital Therapeutics, Novartis

Conference Workshops

Tuesday, February 26th 2019

Conference Workshops at DTx West have been specifically designed to enhance attendee’s learning experiences at the event.

These three-hour sessions will allow you to have your fundamental questions answered by experts in great detail.

If you are looking to understand the basics of Digital Therapeutics and/or you are from a Pharma seeking to learn more about digital therapeutics from a Pharma perspective, then look no further.

Click to download full details of the conference workshops.

Workshop Leaders

Jeffrey Abraham, Vice President, Market Access & Trade, Akili Interactive
Anil Jina, Senior Vice President, Head of Medical Affairs, Akili Interactive
9:00  Presentation: What is the Current State of Play with the Digital Therapeutics Industry?
9:30  Breakout Discussions

Splitting into smaller working groups, each group will discuss their current views on digital therapeutics as a concept and their views on the different facets of the industry.

  • Are we comfortable with the definition of a digital therapeutic?
  • Generally speaking, how do payers, pharma and regulatory authorities view digital therapeutics?
  • What lessons can we draw on from working with other related industries?
  • What are our thoughts on the other similar digital medicine approaches out there?
  • What remaining questions do we have about digital therapeutics?
10:30  Refreshment Break
11:00  Feedback Discussions

Representative(s) from each group share the main points from their discussion to the whole group. Additional questions form moderators and other group members will be raised during this collaborative discussion.

12:00  End of Workshop

Leave this workshop with: 

  • Fundamental questions answered around what a digital therapeutic is being defined as compared to other digital interventions
  • A deeper understanding of the current payer and provider perspectives on digital therapeutics and how these are looking to be advanced
  • Up-to-date information on the different ways pharma are involved in the industry
  • A fundamental understanding of the current regulatory pathways in and around the industry
  • A stronger appreciation of the crucial questions facing the industry that will be tackled during the rest of the Summit

Workshop Leaders

James Musick, Vice President & Head, Neurology Patient Technology, UCB
Chris Wasden, Head of Pharma, Happify
1:00  Presentation: What are the Current Sentiments from Pharma Towards Digital Therapeutics?
1:30  Breakout Discussions

Splitting into smaller working groups, each group will discuss their own thoughts and pharma’s current
thoughts on digital therapeutics and what it is going to take to make DTx-pharma partnerships successful.

  • What is our understanding of the expectations from different types of DTx-pharma partnerships?
  • How do digital therapeutics fit into the short-term and long-term goals of pharma?
  • Are pharma more excited about the therapeutic entity or the data produced by digital therapeutics?
  • How should pharma adapt their mindsets to maximize the impact of their work with digital therapeutics?
  • How do digital therapeutic companies needs to adapt to maximize the impact of their work with pharma?
2:30  Refreshments
3:00  Feedback Discussions

Representative(s) from each group share the main points from their discussion to the whole group. Additional questions form moderators and other group members will be raised during this collaborative discussion.

4:00  End of Workshop

Leave this workshop with: 

  • Deeper understanding of the current ways pharma are partnering with digital therapeutics companies
  • Full clarification on the expectations pharma have when in a working partnership with digital therapeutic companies compared to purely investing in them
  • Discussion points around how pharma currently view digital therapeutics in their short-term and long-term strategies
  • Understanding around how different departments in pharma will impact their work in this industry and where a change of mindset is needed
  • An understanding of why some pharma are still reluctant to partner with digital therapeutic companies

Summit Agenda

Click to download our full event agenda.

8:00  Registration, Breakfast & Networking
9:00  Chair’s Opening Remarks & Setting the Scene

Joel Sangerman, Chief Commercial Officer, Click Therapeutics

Digital Therapeutics: Setting-up for Commercial Success
9:10  Keynote Presentation: Lessons Learnt from the Frontline of Digital Therapeutics

Anand Iyer, Chief Strategy Officer, WellDoc

9:35  Panel: What is it Going take for Digital Therapeutics to Succeed Commercially?

Eugene Borukhovich, Global Head, Digital Health Incubation & Innovation, Bayer
Anand Iyer, Chief Strategy Officer, WellDoc
Eddie Martucci, Chief Executive Officer, Akili Interactive
Brent Vaughan, Chief Executive Officer, Cognoa
Alex Waldron, Chief Commercial Officer, Pear Therapeutics

10:20  Morning Refreshments & Networking
11:00                                                                Under the Microscope: Crucial DTx Questions


These small group discussions provide a unique opportunity to get into the key detail of the challenges and opportunities of crucial questions facing digital therapeutics. Each session has been curated to bring expert moderators together in order for attendees to find questions in a peer-to-peer format.  

Attendees will be able to attend 3 roundtables, which are 30 minutes each. Get ready for plenty of takeaways in this 90 minute session!

Roundtable 1:  How do you Transition from Being a Digital Health Company to a Digital Therapeutics Company?
Roundtable 2:  What Partnership Models are Companies Adopting to Accelerate Development and Commercialization?

Giangiacomo Rocco di Torrepadula, Chief Executive Officer & Co-Founder, AMICOMED

Roundtable 3: How are Patient Engagement Strategies Being Applied to Digital Therapeutics?
Roundtable 4: Working with a Payer – From Medical Policy to Commercialization

Debra Reisenthel, President & CEO, Palo Alto Health Sciences
Matthew Tucker, Executive Director, Marketing Strategy, Highmark Health

Roundtable 5:  How do you Develop and Leverage Evidence to Drive Digital Therapeutic Adoption and Use?
Roundtable 6:  What do Digital Therapeutic Companies need to Display to Investors to Secure Funding?

Sasha Said, Vice President, Leerink Transformation Partners

12:30  Long-Table Lunch & Networking
Building for Long-Term Success and Scalability
2:00  Presentation: The Evolution of Digital Therapeutics Commercialization and Scalability

Sean Duffy, Co-Founder & Chief Executive Officer, Omada Health

2:25  Presentation: Globally Scaling Digital Therapeutics for Long-Term Success

Peter Hames, Co-Founder & Chief Executive Officer, Big Health

2:50  Panel: Why are Companies Now Starting to Pivot Toward Digital Therapeutics?

Moderator: Adam Kaufman, President & Chief Executive Officer, Canary Health
Megan Jones-Bell, Chief Scientific OfficerHeadspace
Ed Cox, Chief Executive OfficerDthera Sciences
David Stevenson, Managing Director, Merck Global Health Innovation Fund

3:30   Afternoon Refreshments & Networking
Adoption and Implementation
4:00  Panel: The In’s and Out’s of the Regulatory Approval Pathways

Moderator: David Amor, Vice President, Quality & Regulatory AffairsPear Therapeutics
Scott Kellogg, Senior Vice President, Medical Devices, Akili Interactive
Taylor Mahan-Rudolph, Director, Quality & RegulatoryPropeller Health 
Austin Speier, Chief Strategy Officer, Click Therapeutics

4:45  Panel: How do Digital Therapeutics need to Adapt to The Healthcare System to be Routinely Prescribed?

Moderator: Sharief Taraman, Chief Medical OfficerCognoa  |  Chief of Neurology,  Children’s Hospital of Orange County
Rosemary Ku
, Urgent Care PhysicianKaiser Permanente  |  Founder, Executive Director, Cure Chronic Disease
Stephanie Tilenius, Chief Executive Officer & Founder, Vida Health

5:30  Drinks Reception
Download Agenda to access full details of the event…
8:00  Breakfast & Networking
9:00  Chair’s Opening Remarks

Mette Dyhrberg, Chief Executive Officer, Mymee

Pharma & Digital Therapeutics
9:10   Presentation: Commercializing and Scaling Prescription Digital Therapeutics

André Heeg, Head of Digital, Sandoz

9:35  Panel: Pharma and Digital Therapeutics: A Match Made in Heaven?

Seth Coombs, Vice President, Oncology & Injectable Products, Sandoz
David Klein, Chief Executive Officer, Click Therapeutics
Ruchita Sinha, Senior Director, Investment, Sanofi Ventures
Jeremy Sohn, VP & Global Head, Digital Business Development & Licensing, Novartis

10:20  Morning Refreshments & Networking
The Next Wave of Digital Innovation
10:50  Presentation: European Perspective on Digital Therapeutics – Fitting into Universal Healthcare Systems and Beyond

Matthias Zenker, Partner, GAIA AG

11:15  Presentation: Evidence-based Digital Interventions Using Music and Neuroscience

Owen McCarthy, Co-Founder & President, MedRhythms Inc.

11:40  Presentation: Pivoting from Digital Health to Digital Therapeutics in Alcohol Behavioural Change

Chris Raine, Founder & Chief Executive Officer, Hello Sunday Morning

12:05  Long-Table Lunch & Networking
Digital Therapeutic Market Consolidation
1:30  Panel: How and When Will the Digital Therapeutics Market Consolidate?

David Kim, CEO, DigiTx Partners
Brian Harris, Co-Founder & CEO, MedRhythms Inc.
Shahram Seyedin-Noor, Founder & General Partner, Civilization Ventures

2:20  Chair’s Summary

Mette Dyhrberg, Chief Executive Officer, Mymee

2:30  Close of DTx West 2019
Download Agenda to access full details of the event…

“DTx is a great event! There is a great mix of digital innovators and large companies which delivered high-quality content. I learn a lot and it’s great to see this community come together and have authentic interactions”

Adam Kaufman, CEO, Canary Health

DTx West Venue

The Marriot, San Mateo

We strive to provide inspirational venues that can provide the space needed for an open and widely networked event.

The 2019 summit is being held in the Marriot San Mateo,  a contemporary hotel just 10 minutes from SFO airport.

Blending the look and feel of a first class resort with comfort and state of the art conference amenities this venue is the perfect place for learning, networking and relaxing.

Details of our exclusive delegate rates are included in the welcome pack sent following registration.

Book early to enjoy the best possible rates! All events in the DTx series have sold out and some people missed out at DTx East as the hotel was full when they called to book.

Registration

Sponsorship

The DTx summits are the premier events for senior executives from DTx companies, Pharma, Investors, HCPs and Payers.

DTx West 2019 is the third summit in the series, the first two were sell-outs.  We are expecting 200 people at the summit in San Mateo, which is what our attendees and sponsors tell us is the optimum size

We believe that getting the right mix of sponsors is critical for a successful summit for you and our attendees.  The DTx summit provides a rare opportunity to showcase your business to a world class audience.

You will be impressed with our service and truthfulness.  We will be honest with you throughout the process from deciding which option is right for you to delivery on-site.

With 5 companies confirmed pre-launch, sponsor and supporter spaces are selling fast. Get in touch today to learn more to avoid missing out!

Contact Us

Register For The Event

For pricing and booking options please click the button to go to the registration page.